



Onxeo meets US Investors during “French Life Sciences Days” event in New York on June 17 & 18, 2015

Paris (France), Copenhagen (Denmark), June 3, 2015 – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, announced today its participation in the “French Life Sciences Days” to be held in New York on June 17 & 18, 2015.

Initiated by France Biotech, the event “French Life Sciences Days” aims to bring together French Life Sciences companies listed on stock market with the North American financial community. Given the great success of its first edition of June 2014, France Biotech renews this event to enable innovative SMEs to promote their achievements and attractiveness towards specialized US-based investors.

During this event, about 20 French Biotech Medtech and Cleantech, including Onxeo will present and hold face-to-face meetings with specialized North American investment funds, banks, financial analysts. This event will also be widely covered by the medias in France and in the US.

« US investors show a growing level interest in the French Biotech companies’ innovations and breakthroughs. The “Life Sciences Days” event in New York is an excellent opportunity for Onxeo to reinforce its visibility with these specialized US investors, to strengthen their knowledge about recent company’s achievements and future growth strategy », comments Judith Greciet, CEO of Onxeo and board member of France Biotech association.

“French Life Sciences Days”, June 18, 2015 - W Hotel, 541 Lexington Avenue, New York, NY 10022, United States

About « French Life Sciences Days »

This new initiative of France Biotech aims to strengthen links between French listed companies and investors from different countries, and thus to promote exchange of information while demonstrating the strength of our financial market. It aims to bring together the key players in Paris (banks, brokers, analysts, auditors, lawyers, communication agencies) combined in a sponsorship committee what will accompany the entrepreneurs. On this occasion, the French companies of Life Sciences listed on NYSE Euronext will present their innovations and breakthroughs to international investors.

About France Biotech Biotech

France Biotech brings together French life science companies and their expert partners. Its mission is to support the development of the French life sciences by working for a favorable legislative and fiscal environment. France Biotech catalyzed the French government's creation of a special fiscal status for start ups in 2004 and continues to act as an advocate for this innovative sector. The organization is currently chaired by Pierre-Olivier Goineau, Co-Founder of ERYTECH Pharma. France Biotech has over 150 members and is governed by a Board of 20 life science entrepreneurs.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives designed to “make the difference”. The Onxeo team is determined to develop innovative medicines that provide patients with hope and significantly improve their lives.

Key orphan oncology products at the advanced development stage are:

Livatag® (doxorubicin Transdrug™): Phase III in hepatocellular carcinoma

Validive® (clonidine Lauriad®): Phase II in severe oral mucositis: Positive final results

Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma

For more information, visit the website www.onxeo.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference Document filed with the AMF on April 14, 2015, which is available on the AMF website (<http://www.amf-france.org>) or on the company's website (www.onxeo.com).

Contacts :

Judith Greciet, CEO

j.greciet@onxeo.com

Nicolas Fellmann, CFO

n.fellmann@onxeo.com

+33 1 45 58 76 00

Caroline Carmagnol

onxeo@alizerp.com

+33 6 64 18 99 59

To receive our press releases and newsletters, please register on: <http://www.onxeo.com/en/newsletter/>

Follow us on twitter @Onxeo_